The company also entered into a sales agreement with Cowen and Company to offer up to $75 million of its common stock for sale.
As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.
WUSTL bioinformatics spinout PierianDx disclosed in an SEC filing that it has raised slightly more than $3 million of a $5 million offering.
The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
The company borrowed $205 million in revolving loans from the credit facility, which matures on December 23, 2021.
The gene editing company has notified the SEC it plans to trade on the Nasdaq beginning in 2016 under the ticker “EDIT.”
The firm is selling stock and warrants to purchase stock to raise money for general corporate purposes and working capital.
Helicos said it will require "significant additional capital" before the end of the year to fund its operations. The company's "current financial resources raise substantial doubt about its ability to continue as a going concern."
The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.
In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.